By Lisa Kerner
Erie, Pa., April 12 - Novagali Pharma SA said it has secured €26 million in series C financing, bringing to €44 million the total capital raised by the company since its inception in 2000.
Proceeds from the latest round will be used to finance clinical trials and research programs, to prepare for product commercialization, and for development projects such as Eyeject, a novel technology for intra and periocular delivery of drugs.
AGF Private Equity and Bernard Chauvin joined the group of Novagali Pharma's investors: 1.2.3. Multinova, Auriga Partners, CDC Entreprises Innovation, Credit Agricole Private Equity, Edmond de Rothschild Investment Partners, FCJE (managed by CDC Entreprises - FP Gestion) and Siparex Ventures.
Located in Evry, France, Novagali is a privately held biopharmaceutical company that develops novel ophthalmic products.
| Issuer: | Novagali Pharma SA
|
| Issue: | Series C financing
|
| Amount: | €26 million
|
| Investors: | AGF Private Equity, Bernard Chauvin, 1.2.3. Multinova, Auriga Partners, CDC Entreprises Innovation, Credit Agricole Private Equity, Edmond de Rothschild Investment Partners, FCJE (managed by CDC Entreprises - FP Gestion) and Siparex Ventures
|
| Announcement date: | April 12
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
